Matches in SemOpenAlex for { <https://semopenalex.org/work/W2353966382> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2353966382 abstract "Objective To investigate the mechanism and influence of budesonide and formoterol fumarate powder for inhalation on airway remodeling and inflammatory mediators in bronchoalveolar lavage fluid(BALF) in patients with mild bronchial asthma(BA).Methods Fifty-two patients with mild BA were randomly divided into three groups.Twenty-two patients in budesonide and formoterol fumarate powder group(group A) were treated with budesonide and formoterol fumarate powder by inhaling every night.Fifteen patients in budesonide group(group B) were treated with budesonide by inhaling every night.Fifteen patients in conventional therapy group(group C) were treated with theophylline controlled release tablets 0.2 g twice daily as well as ventolin aerosol 2 bell three times a day during asthmatic attack.Ten healthy subjects were selected as normal control group(N group).Before treatment and six months after treatment,mucosa biopsies of fiberoptic bronchoscopy was performed;The thickness of bronchial mucosa′s reticular basement membrane(TRBM) and the numbers of airway submucosal myofibroblasts were measured and compared;the levels of transforming growth factor-beta 1(TGF-β1) and matrix metalloproteinase-9(MMP-9) were determined by enzyme-linked immunosorbent assay.Results Before and after treatment,the number of cells in BALF,the number of eosinophilic granulocyte(EOS),the level of TGF-β1,MMP-9,TRBM and the number of airway submucosal myofibroblasts in group A,B,and C were higher than those in N group significantly(P0.01).There was no obvious difference in the indexes among group A,B and C(P0.05).After treatment,the above indexes in group A and B were lower than those in group C(P0.01),there was no obvious difference in the number of BALF and EOS between group A and B(P0.05),but the level of TGF-β1,MMP-9,TRBM and the number of airway submucosal myofibroblasts in group A were lower than those in group B(P0.05).Conclusion Budesonide and formoterol fumarate powder for inhalation can relieve the airway remodeling by inhibiting the airway inflammation." @default.
- W2353966382 created "2016-06-24" @default.
- W2353966382 creator A5068931116 @default.
- W2353966382 date "2011-01-01" @default.
- W2353966382 modified "2023-09-26" @default.
- W2353966382 title "Influence of budesonide and formoterol fumarate powder for inhalation on airway remodeling and inflammatory mediators in bronchoalveolar lavage fluid in patients with mild bronchial asthma" @default.
- W2353966382 hasPublicationYear "2011" @default.
- W2353966382 type Work @default.
- W2353966382 sameAs 2353966382 @default.
- W2353966382 citedByCount "1" @default.
- W2353966382 countsByYear W23539663822015 @default.
- W2353966382 crossrefType "journal-article" @default.
- W2353966382 hasAuthorship W2353966382A5068931116 @default.
- W2353966382 hasConcept C105922876 @default.
- W2353966382 hasConcept C126322002 @default.
- W2353966382 hasConcept C2776042228 @default.
- W2353966382 hasConcept C2776136866 @default.
- W2353966382 hasConcept C2776954882 @default.
- W2353966382 hasConcept C2777714996 @default.
- W2353966382 hasConcept C2777961210 @default.
- W2353966382 hasConcept C2779871671 @default.
- W2353966382 hasConcept C2909086917 @default.
- W2353966382 hasConcept C42219234 @default.
- W2353966382 hasConcept C71924100 @default.
- W2353966382 hasConcept C90924648 @default.
- W2353966382 hasConceptScore W2353966382C105922876 @default.
- W2353966382 hasConceptScore W2353966382C126322002 @default.
- W2353966382 hasConceptScore W2353966382C2776042228 @default.
- W2353966382 hasConceptScore W2353966382C2776136866 @default.
- W2353966382 hasConceptScore W2353966382C2776954882 @default.
- W2353966382 hasConceptScore W2353966382C2777714996 @default.
- W2353966382 hasConceptScore W2353966382C2777961210 @default.
- W2353966382 hasConceptScore W2353966382C2779871671 @default.
- W2353966382 hasConceptScore W2353966382C2909086917 @default.
- W2353966382 hasConceptScore W2353966382C42219234 @default.
- W2353966382 hasConceptScore W2353966382C71924100 @default.
- W2353966382 hasConceptScore W2353966382C90924648 @default.
- W2353966382 hasLocation W23539663821 @default.
- W2353966382 hasOpenAccess W2353966382 @default.
- W2353966382 hasPrimaryLocation W23539663821 @default.
- W2353966382 hasRelatedWork W1930777793 @default.
- W2353966382 hasRelatedWork W2034431047 @default.
- W2353966382 hasRelatedWork W2052589390 @default.
- W2353966382 hasRelatedWork W2086940683 @default.
- W2353966382 hasRelatedWork W2147268177 @default.
- W2353966382 hasRelatedWork W2262959080 @default.
- W2353966382 hasRelatedWork W2412260424 @default.
- W2353966382 hasRelatedWork W2414650175 @default.
- W2353966382 hasRelatedWork W3024635961 @default.
- W2353966382 hasRelatedWork W3028822427 @default.
- W2353966382 hasRelatedWork W3029127381 @default.
- W2353966382 hasRelatedWork W3029294915 @default.
- W2353966382 hasRelatedWork W3029562276 @default.
- W2353966382 hasRelatedWork W3029740665 @default.
- W2353966382 hasRelatedWork W3029750650 @default.
- W2353966382 hasRelatedWork W3030544472 @default.
- W2353966382 hasRelatedWork W3031315954 @default.
- W2353966382 hasRelatedWork W3031654104 @default.
- W2353966382 hasRelatedWork W3032836008 @default.
- W2353966382 hasRelatedWork W3207537871 @default.
- W2353966382 isParatext "false" @default.
- W2353966382 isRetracted "false" @default.
- W2353966382 magId "2353966382" @default.
- W2353966382 workType "article" @default.